Ibritumomab tiuxetan

Medical use

Ibritumomab tiuxetan is used to treat relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma (NHL), a lymphoproliferative disorder, and previously untreated follicular NHL in adults who achieve a partial or complete response to first-line chemotherapy.

The treatment starts with an infusion of rituximab. This may be followed by an administration of indium-111 labeled ibritumomab tiuxetan (111In replaces the 90Y component) to allow the distribution of the medication to be imaged on a gamma camera, before the actual therapy is administered.

Mechanism of action

The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors), allowing radiation from the attached isotope (mostly beta emission) to kill it and some nearby cells. In addition, the antibody itself may trigger cell death via antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. Together, these actions eliminate B cells from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells.

History

Developed by IDEC Pharmaceuticals, now part of Biogen Idec, ibritumomab tiuxetan was the first radioimmunotherapy drug approved by the US Food and Drug Administration (FDA) in 2002 to treat cancer. It was approved for the treatment of people with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL), including people with rituximab refractory follicular NHL. It was given marketing authorization by the European Medicines Agency in 2004 for the treatment of adults with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma but. The authorization lapsed in July 2024, after it wasn't marketed for more than three consecutive years.

In September 2009, ibritumomab tiuxetan received approval from the FDA for an expanded label to include previously untreated people with a chemotherapy response.

Society and culture

Economics

Ibritumomab tiuxetan is under patent protection and not available in generic form. When approved, it was the most expensive medication available given in a single dose, costing over (€30,000) for the average dose. Compared with other monoclonal antibody treatments (many of which are well over $40,000 for a course of therapy), it may be considered cost effective.

References

References

1. (2 March 2009). "Zevalin EPAR".
2. (26 February 2008). "Ibritumomab Tiuxetan".
3. (June 2004). "Antibody-targeted radiation cancer therapy". Nature Reviews. Drug Discovery.
4. [http://whqlibdoc.who.int/druginfo/INN_2000_list43.pdf WHO Drug Information]
5. (May 2011). "Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists". Journal of Nuclear Medicine.
6. (April 2007). "EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)". European Journal of Nuclear Medicine and Molecular Imaging.
7. "Ibritumomab Tiuxetan". US Food and Drug Administration.
8. (24 June 2003). "Idec to Merge With Biogen in $6.8 Billion Deal". The New York Times.
9. (October 2002). "Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma". Expert Review of Anticancer Therapy.
10. (September 2019). "Economics of New Molecular Targeted Personalized Radiopharmaceuticals". Seminars in Nuclear Medicine.
11. (23 June 2004). "Why are the new cancer drugs so expensive?". Slate Magazine.
12. (March 2015). "Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma". Value in Health.